Cover Image

High neuronatin (NNAT) expression is associated with poor outcome in breast cancer

Neuronatin (NNAT) is a proteolipid involved in cation homeostasis especially in the developing brain. Its expression has been associated with the progression of lung cancer, glioblastoma, and neuroblastoma as well as glucose induced apoptosis in pancreatic cells. We performed a retrospective study o...

Full description

Saved in:
Bibliographic Details
Main Authors: Naß, Norbert (Author) , Sel, Saadettin (Author)
Format: Article (Journal)
Language:English
Published: 24 May 2017
In: Virchows Archiv
Year: 2017, Volume: 471, Issue: 1, Pages: 23-30
ISSN:1432-2307
DOI:10.1007/s00428-017-2154-7
Online Access:Resolving-System, Volltext: http://dx.doi.org/10.1007/s00428-017-2154-7
Verlag, Volltext: https://link.springer.com/article/10.1007/s00428-017-2154-7
Get full text
Author Notes:Norbert Nass, Sarah Walter, Dörthe Jechorek, Christine Weissenborn, Atanas Ignatov, Johannes Haybaeck, Saadettin Sel, Thomas Kalinski
Description
Summary:Neuronatin (NNAT) is a proteolipid involved in cation homeostasis especially in the developing brain. Its expression has been associated with the progression of lung cancer, glioblastoma, and neuroblastoma as well as glucose induced apoptosis in pancreatic cells. We performed a retrospective study of 148 breast cancer specimens for NNAT expression by immunohistochemistry to evaluate this protein as a prognostic marker for breast cancer. We found a high NNAT immunoreactivity score (by multivariate cox regression) to be an independent prognostic marker for relapse-free (hazard ratio HR = 3.55, p = 0.002) and overall survival (HR = 6.29, p < 0.001). However, NNAT expression was not associated with classical parameters such as hormone receptor expression (p = 0.86) or lymph node metastasis (p = 0.83). Additional independent risk factors in this study population were tumor size (≤2 cm; overall survival: HR = 0.36, p = 0.023; relapse-free survival: HR = 0.26, p < 0.01) and blood vessel infiltration (overall survival: HR = 0.34 p < 0.01). NNAT expression determined by immunohistochemistry might therefore become a helpful additional biomarker to identify high-risk breast cancer patients.
Item Description:Published online 24 May 2017
Gesehen am 25.07.2018
Physical Description:Online Resource
ISSN:1432-2307
DOI:10.1007/s00428-017-2154-7

Similar Items